3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
2
Active not recruiting
2
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
27
Neoplasms
25
Lung Neoplasms
12
Uterine Cervical Neoplasms
11
Colorectal Neoplasms
10
Colonic Neoplasms
8
Motor Activity
7
Urinary Bladder Neoplasms
6
Rectal Neoplasms
6
Vulvar Neoplasms
5
Obesity
5
Endometrial Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Head and Neck Neoplasms
4
Anxiety Disorders
4
Stomach Neoplasms
3
Sarcoma
3
Prostatic Neoplasms
3
Papillomavirus Infections
3
Lymphoma
3
Hematopoietic and Lymphoid System Neoplasm
3
Hematologic Neoplasms
3
Depression
3
Carcinoma, Ovarian Epithelial
3
Breast Carcinoma In Situ
3
Vaginal Neoplasms
2
Testicular Neoplasms
2
Smoking Cessation
2
Skin Neoplasms
2
Interventions
Carboplatin
177
Paclitaxel
176
Bevacizumab
72
Topotecan
55
liposomal doxorubicin
54
Gemcitabine
53
Cisplatin
46
Docetaxel
39
Cyclophosphamide
37
olaparib
32
Filgrastim
31
pembrolizumab
29
Doxorubicin
26
niraparib
24
Taxes
23
Drug Therapy
23
Peripheral Blood Stem Cell Transplantation
20
Etoposide
17
veliparib
15
Nivolumab
14
sargramostim
13
Surveys and Questionnaires
13
Immunoglobulin G
13
Disulfides
13
pazopanib
12
Ifosfamide
12
Albumin-Bound Paclitaxel
12
durvalumab
11
atezolizumab
11
Trabectedin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Ovarian Neoplasms
×
Methods
×
Clear all
NCT05939440
2025-06-05
P-COC
University of Alabama at Birmingham
Phase NA
Completed
60 enrolled